The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey
Abstract Background Withholding live-attenuated vaccines in patients using interleukin (IL)-1 or IL-6 blocking agents is recommended by guidelines for both pediatric and adult rheumatic diseases, since there is a risk of infection in an immune suppressed host. However, this has never been studied. T...
Main Authors: | Jerold Jeyaratnam, Nienke M. ter Haar, Helen J. Lachmann, Ozgur Kasapcopur, Amanda K. Ombrello, Donato Rigante, Fatma Dedeoglu, Ezgi H. Baris, Sebastiaan J. Vastert, Nico M. Wulffraat, Joost Frenkel |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-03-01
|
Series: | Pediatric Rheumatology Online Journal |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12969-018-0235-z |
Similar Items
-
Schnitzler syndrome, a rare autoinflammatory disease. Complete response to IL-1 blockade
by: Paola Faggioli, et al.
Published: (2017-12-01) -
Innate type 1 immune response, but not IL-17 cells control tuberculosis infection
by: Noria Segueni, et al.
Published: (2021-04-01) -
Editorial: IL-1 Inhibition
by: Francesca Oliviero, et al.
Published: (2019-02-01) -
Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports
by: Simone Ferrero, et al.
Published: (2021-03-01) -
The central role of anti-IL-1 blockade in the treatment of monogenic and multifactorial autoinflammatory diseases.
by: Silvia eFederici, et al.
Published: (2013-10-01)